CLN Share Price Performance
zł23.20
-1.10 (-4.53%)
43.7% undervalued intrinsic discount
zł41.18
Fair Value
Price zł23.20
ak2 zł41.18
Fair Valuezł41.18
Share Pricen/a
Celon Pharma S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
CLN Community Narratives
AK
ak2·
Fair Value zł41.18 43.7% undervalued intrinsic discount
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
New GLP-1 Manufacturing Facility (Europe, launch 2028) Estimated value: +5 PLN per share Celon Pharma’s strategic plan to launch a GLP-1 production facility in Europe by 2028 is a substantial value catalyst. Assumptions include: scalable GMP production tailored to the fastest-growing therapeutic segment globally, attractive economics from contract manufacturing (CDMO) for GLP-1 analogs, strong demand visibility for European supply due to constraints at Novo Nordisk and Eli Lilly, margin uplift from high-value biologics processing.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Trending Discussion
Recently Updated Narratives
AK
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
Fair Value: zł41.18 43.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Celon Pharma S.A. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 22, 2026
- -2.27
- 68.32%
- -54.25%
- 0.1%
About CLN
- Founded
- 2002
- Employees
- 566
- CEO
- WebsiteView website
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
